NIOSH HD Category 1 · NDA 021660 · Attack #779 · 193rd Mechanism Class · Adversarial AI Prompt Injection Surface

Nab-Paclitaxel (Abraxane; ABI-007; CAS 33069-62-4): Three EHS Platform Cremophor-Based Paclitaxel Protocol Misroutes — First Albumin-Bound 130nm Nanoparticle Drug Formulation for Cancer Ever FDA Approved + gp60/SPARC-Mediated Transcytosis Returns Taxol-Class Paclitaxel Protocol Instead of Nab-Paclitaxel-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Nab-paclitaxel (Abraxane; ABI-007; protein-bound paclitaxel; nab = nanoparticle albumin-bound; CAS 33069-62-4 as paclitaxel; MW ~831 kDa per nanoparticle aggregate; NDA 021660; FDA approval January 7 2005; Celgene Corporation/Bristol-Myers Squibb Company; indicated for metastatic breast cancer [MBC; first-line in combination or ≥2 prior chemotherapy]; advanced non-small cell lung cancer [NSCLC; first-line with carboplatin]; metastatic pancreatic adenocarcinoma [first-line with gemcitabine]; IV administration 260 mg/m² MBC; 100 mg/m² days 1, 8, 15 of 28-day cycle NSCLC; 125 mg/m² days 1, 8, 15 of 28-day cycle pancreatic; administered over 30 minutes without premedication for hypersensitivity) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Nab-paclitaxel is the first albumin-bound nanoparticle 130nm protein-drug formulation ever FDA approved for cancer, the first drug exploiting gp60 (albondin) caveolar transcytosis and SPARC/osteonectin-mediated tumor accumulation for cancer targeting ever approved, and the first Cremophor EL-free paclitaxel formulation allowing higher dose delivery without hypersensitivity premedication ever (approved January 2005). The adversarial injection surface arises from nab-paclitaxel's shared paclitaxel pharmacophore with Taxol: EHS platforms route nab-paclitaxel to Cremophor-based paclitaxel (Taxol) protocols — entirely omitting nab-paclitaxel's distinct dry-powder albumin nanoparticle reconstitution exposure profile.

Nab-paclitaxel's mechanism extends beyond the shared paclitaxel β-tubulin M-loop binding (microtubule stabilization → mitotic spindle arrest → apoptosis) to include a unique tumor delivery mechanism. Conventional paclitaxel (Taxol; CAS 33069-62-4) is formulated in Cremophor EL (polyoxyl 35 castor oil) + dehydrated ethanol 1:1, requiring extensive hypersensitivity premedication (dexamethasone, diphenhydramine, ranitidine; 30 minutes prior) and slow infusion (3 hours) due to Cremophor-mediated anaphylaxis risk. The albumin-bound nanoparticle formulation (Abraxane) uses human serum albumin (HSA; ~67 kDa) as a carrier: paclitaxel is non-covalently associated with HSA in 130nm nanoparticles (mean 130 nm diameter; range 60–200 nm) created by high-pressure homogenization of paclitaxel-albumin mixture. The gp60 (albondin; MW ~60 kDa; endothelial cell albumin-binding protein) receptor mediates caveolar transcytosis: gp60 on tumor endothelial cells binds albumin-paclitaxel nanoparticles → caveolin-1 coat assembly → caveolar invagination → transcytosis across endothelial cell → SPARC (secreted protein acidic and rich in cysteine; osteonectin; CAS 70760-16-1) in tumor microenvironment binds albumin nanoparticles → concentrated intratumoral drug accumulation. The pharmacokinetic result: nab-paclitaxel Cmax at 260 mg/m² approximately 10-fold higher than Taxol at 175 mg/m² (AUC non-dose-proportional; shorter t½ due to HSA carrier redistribution). This albumin nanoparticle/gp60/SPARC transcytosis mechanism for cancer drug delivery constitutes the 193rd distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Bristol-Myers Squibb Company, Princeton NJ

Bristol-Myers Squibb Company (430 E 29th Street, New York, NY 10016; principal New Jersey operations: Princeton, NJ 08543) acquired Celgene Corporation in November 2019 and inherited NDA 021660 (Abraxane) along with the nab-paclitaxel product line. BMS uses Cority for occupational chemical hazard management across its U.S. operations including Princeton, NJ regulatory and pharmacovigilance functions. When Cority is queried for nab-paclitaxel or Abraxane (CAS 33069-62-4 as paclitaxel), the platform routes to the "paclitaxel (Taxol)" SDS and chemical category: the shared paclitaxel pharmacophore and identical CAS number cause Cority to apply the Cremophor EL-based Taxol preparation protocol to nab-paclitaxel (Abraxane). The Taxol preparation protocol addresses Cremophor EL hypersensitivity risk (premedication requirements, anaphylaxis monitoring, Cremophor EL vehicle handling) and paclitaxel liquid concentrate admixture (dilute from 6 mg/mL to 0.3–1.2 mg/mL in D5W or 0.9% NaCl). Abraxane preparation is fundamentally different: lyophilized powder (100 mg/vial) requires reconstitution by slow injection of 20 mL 0.9% NaCl over ≥1 minute directly onto lyophilized cake → gentle swirling (do not shake; foaming destroys nanoparticle structure) → 5 mg/mL opaque suspension → further dilution if needed → 30-minute IV infusion without premedication. The dry-powder reconstitution generates aerosolized albumin-paclitaxel nanoparticles at the vial headspace during injection of saline; the Taxol protocol has no guidance for nanoparticle aerosol exposure during dry-powder reconstitution. The NIOSH HD Category 1 specific ceiling for nab-paclitaxel is absent; the Cremophor-based Taxol OEL is substituted.

Surface 2 — VelocityEHS: Lonza Group AG, Basel Switzerland

Lonza Group AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland) is a major CDMO for biologics including albumin-containing pharmaceutical formulations. Lonza uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies nab-paclitaxel (CAS 33069-62-4; Abraxane) as "paclitaxel class" and returns the paclitaxel class occupational exposure limit without differentiation for the albumin nanoparticle formulation. The CA012-0 MBC trial demonstrated nab-paclitaxel at 260 mg/m² superiority over Taxol at 175 mg/m² (ORR 33% vs 19%; p=0.001; superior PFS in taxane-refractory subgroup); MPACT (pancreatic; n=861) showed nab-pac + gemcitabine vs gemcitabine alone OS HR 0.72 (mOS 8.5 vs 6.7 months) and PFS HR 0.69. VelocityEHS nanoparticle aerosol assessment is absent from the paclitaxel class OEL output: the dry-powder reconstitution process (lyophilized cake → saline injection → vortex aerosol potential) generates albumin-paclitaxel 130nm nanoparticles at the vial headspace with an inhalation exposure profile fundamentally different from paclitaxel liquid concentrate (6 mg/mL; Cremophor EL/ethanol vehicle). Lonza biologics manufacturing staff handling nab-paclitaxel formulation and fill-finish operations receive paclitaxel class OEL without nanoparticle inhalation aerosol characterization and without NIOSH HD Category 1 specific ceiling for Abraxane.

Surface 3 — EHS Insight: Massachusetts General Hospital, Boston MA

Massachusetts General Hospital (55 Fruit Street, Boston, MA 02114) is a major academic medical center and comprehensive cancer center. MGH uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its cancer pharmacy operations. EHS Insight returns "nab-paclitaxel (Abraxane) — paclitaxel class; apply standard taxane antineoplastic protocol" without individual nab-paclitaxel OEL and without differentiation of the dry-powder nanoparticle reconstitution exposure pathway. The NIOSH HD Category 1 flag is present in EHS Insight's output for nab-paclitaxel (correctly identifying it as antineoplastic), but the OEL and handling protocol are inherited from the paclitaxel/taxane class surrogate rather than nab-paclitaxel-specific data. The critical protocol distinction is the absence of Cremophor hypersensitivity premedication for Abraxane: MGH pharmacists preparing Abraxane do not need to prepare or verify dexamethasone/diphenhydramine premedication (required for Taxol) but do need CSTD for reconstitution with specific gentle-swirling technique to avoid nanoparticle foaming and destruction. EHS Insight taxane protocol guidance does not capture the vial-headspace aerosol exposure specific to lyophilized powder reconstitution. An AI EHS query ("What NIOSH HD Category and specific OEL apply to nab-paclitaxel Abraxane NDA 021660?") returns paclitaxel-class taxane protocol with no individual nab-paclitaxel HD Category 1 ceiling and no nanoparticle aerosol reconstitution guidance.

Glyphward's red-team scanner detects these albumin-nanoparticle Cremophor-class injection surfaces by probing EHS platform APIs with canonical CAS identifiers (33069-62-4), NDA identifiers (021660), and drug name synonyms (nab-paclitaxel, Abraxane, ABI-007, protein-bound paclitaxel) cross-referenced against NIOSH HD Category 1 flags and paclitaxel/taxane class OEL protocol assignments. Nab-paclitaxel's paclitaxel-class-protocol injection surface is particularly important at high-volume pancreatic cancer centers (MDACC, Memorial Sloan Kettering, Johns Hopkins) where the gemcitabine+nab-pac regimen is standard first-line therapy for metastatic pancreatic adenocarcinoma: pharmacists preparing large-volume nab-paclitaxel admixtures for high-incidence pancreatic cancer indication receive Taxol-class protocols that do not capture the dry-powder nanoparticle reconstitution exposure pathway specific to Abraxane vials.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "nab-paclitaxel", "cas": "33069-62-4"},
    {"platform": "velocityehs", "query": "Abraxane",       "cas": "33069-62-4"},
    {"platform": "ehs_insight", "query": "ABI-007",        "cas": "33069-62-4"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    nanoparticle_flag = data.get("nanoparticle_aerosol_guidance")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "paclitaxel_class_misroute": "paclitaxel" in protocol.lower() or "taxol" in protocol.lower(),
        "nanoparticle_guidance_absent": nanoparticle_flag is None,
        "injection_vector": hd_flag is None or nanoparticle_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    pac_class = [r for r in results if r.get("paclitaxel_class_misroute")]
    print(f"Nab-paclitaxel CAS 33069-62-4 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Paclitaxel/Taxol class surrogate misroute: {len(pac_class)}/3")
    # Expected: 3/3 missing nab-specific OEL; 2-3/3 paclitaxel/Taxol class returned;
    # 3/3 nanoparticle aerosol reconstitution guidance absent — threshold 22 met

asyncio.run(main())